ChromaDex Responds to Short Attack

Amyris Signs Five Year Biofene ® Supply Agreement with leading Global Nutraceuticals Company with Over $100 Million of Expected Value

EMERYVILLE, Calif., April 27, 2016 -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it has executed a five year Biofene^® supply agreement with a global nutraceuticals company. This new, long-term agreement replaces the parties’ one-year purchase agreement, which was previously announced on January 4, 2016. Under the new supply agreement, the customer has agreed to a larger Biofene purchase in 2016 with an expected revenue contribution of approximately $9 million and to minimum annual purchase commitments in each of the remaining years of the agreement. In addition, under the new agreement, Amyris is entitled to a quarterly value-share arrangement on the sales of the customer’s product made from the purchased Biofene. Amyris expects total revenue from the five-year agreement to be more than $100 million. In year-five of the supply agreement term, the agreement is projected to generate approximately $40 million of annual revenue, which Amyris expects will be renewed at that level in subsequent years.

Century Reports Fourth Quarter 2015 Financial Results

CHICAGO, IL--(Feb 18, 2016) - Century Aluminum Company (NASDAQ: CENX) reported a net loss of $43.1 million ($0.50 per share) for the fourth quarter of 2015. Results were favorably impacted by a $23.5 million ($0.25 per share) lower of cost or market inventory adjustment and $3.4 million ($0.04 per share) related to non-cash, non-recurring post-retirement benefits. Results were negatively impacted by a $3.5 million charge ($0.04 per share) related to the partial curtailment of operations at Hawesville and Mt. Holly, a $5.0 million charge ($0.05 per share) for depreciation related to Mt. Holly purchase accounting and an $11.6 million impairment charge ($0.12 per share) at BHH. After consideration of these items, the company reported an adjusted net loss of $49.9 million and an adjusted loss per share of $0.53 for the fourth quarter.

For the fourth quarter of 2014, Century reported net income of $75.8 million ($0.78 per share). Results were positively impacted by $21.5 million ($0.22 per share) for purchase accounting related to the Mt. Holly acquisition and negatively impacted by $5.0 million ($0.05 per share) in non-cash, non-recurring pension charges and by $2.6 million ($0.03 per share) related to the separation of former senior executives.

Cytec Announces Merger Agreement with Solvay

Woodland Park, NJ, July 29, 2015 - Cytec Industries Inc. (CYT) announced today it has entered into a definitive merger agreement with Brussels-based Solvay.   The total cash consideration will amount to US$5.5 billion, corresponding to an enterprise value of US$6.4 billion.  The transaction price per share of $75.25 represents a premium of 28.9% compared to our closing price of $58.39 on July 28, 2015 and a premium of 26.9% compared to the volume weighted average closing share price over the last three months.

Shane Fleming, Chairman, President and Chief Executive Officer commented, "We are excited to be joining a preeminent global chemical company with leading market positions and a similar growth strategy to Cytec`s.  This union will enhance our businesses ability to drive their strategy of value creation through strengthening and leveraging our market and technology leadership positions in high growth end markets."